In the latest quarter, 4 analysts provided ratings for Baxter Intl (NYSE:BAX), showcasing a mix of bullish and bearish perspectives.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $45.75, along with a high estimate of $54.00 and a low estimate of $40.00. This current average reflects an increase of 1.67% from the previous average price target of $45.00.

Breaking Down Analyst Ratings: A Detailed Examination

A comprehensive examination of how financial experts perceive Baxter Intl is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Baxter Intl's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Baxter Intl analyst ratings.

Get to Know Baxter Intl Better

Baxter Intl: Delving into Financials

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: Over the 3 months period, Baxter Intl showcased positive performance, achieving a revenue growth rate of 2.25% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 1.03%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): Baxter Intl's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.45%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.13%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: Baxter Intl's debt-to-equity ratio surpasses industry norms, standing at 1.73. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.